trending Market Intelligence /marketintelligence/en/news-insights/trending/HwSUEqQMxWNxx0u2ITxN6g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Revance prices common stock offering to raise $100M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Revance prices common stock offering to raise $100M

Revance Therapeutics Inc. priced its underwritten public offering of 5,882,353 common shares at $17 apiece.

The Newark, Calif.-based biotechnology company expects to raise about $100 million in gross proceeds from the offering. It has also granted the underwriters an option to buy up to an additional 882,352 shares.

Revance, which is developing a product that would compete with Allergan PLC's Botox, plans to use the proceeds for working capital and general corporate purposes. The funds will also cover expenses related to clinical trials, research and development, general and administrative activities and capital investments.

The offering is expected to close Jan. 22.

Goldman Sachs & Co. LLC and Cowen and Piper Jaffray are acting as joint book-running managers for the offering, with Guggenheim Securities as lead manager.